Octavio Espinoza - 01 Nov 2022 Form 3/A - Amendment Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Chief Financial Officer
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Issuer symbol: LGND
Transactions as of: 01 Nov 2022
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 02 Jul 2025, 19:03:42 UTC
Date Of Original Report: 02 Jul 2025
Next filing: 10 Nov 2022
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Espinoza Octavio	Chief Financial Officer	555 HERITAGE DRIVE, SUITE 200, JUPITER	By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza	02 Jul 2025	0001905248

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LGND	Common Stock						1,696	01 Nov 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This amendment (the "Amendment") is being filed to correct the Form 3 filed with the Securities and Exchange Commission on November 1, 2022 (the "Original Form 3"), which inadvertently understated the Reporting Person's direct holdings of Ligand Pharmaceuticals, Inc. common stock ("Common Stock") by 1,696 shares. This Form 3/A is deemed to update the number of securities reported as beneficially owned in any Forms 4 subsequently filed by the reporting person through the date hereof.

Content

This amendment (the "Amendment") is being filed to correct the Form 3 filed with the Securities and Exchange Commission on November 1, 2022 (the "Original Form 3"), which inadvertently understated the Reporting Person's direct holdings of Ligand Pharmaceuticals, Inc. common stock ("Common Stock") by 1,696 shares. This Form 3/A is deemed to update the number of securities reported as beneficially owned in any Forms 4 subsequently filed by the reporting person through the date hereof.